Ypsomed Holding AG (CH:YPSN)
:YPSN
YPSN Stock Chart & Stats
CHF307.50
-CHF5.00(-1.41%)
At close: 4:00 PM EST
CHF307.50
-CHF5.00(-1.41%)
Day’s Range― - ―
52-Week RangeCHF260.50 - CHF441.50
Previous CloseN/A
Volume2.70K
Average Volume (3M)17.31K
Market Cap
CHF3.82B
Enterprise ValueCHF3.90B
Total Cash (Recent Filing)CHF36.30M
Total Debt (Recent Filing)CHF110.00M
Price to Earnings (P/E)7.7
Beta0.49
Next Earnings
May 27, 2026Next Dividend Ex-DateN/A
Dividend Yield0.67%
Share Statistics
EPS (TTM)10.19
Shares Outstanding13,649,739
10 Day Avg. Volume12,508
30 Day Avg. Volume17,306
Financial Highlights & Ratios
PEG Ratio4.54
Price to Book (P/B)6.82
Price to Sales (P/S)6.19
P/FCF Ratio-35.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)13.29
Revenue Forecast (FY)CHF703.65M
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthSustained high top-line expansion (36.5% year) indicates expanding commercial traction with pharma partners and end markets. Durable because large drug-device contracts and recurring consumable sales typically drive multi-year volumes and predictable revenue streams once products are commercialized.
High And Sustainable Margins In Delivery SystemsA 32.4% EBIT margin in Delivery Systems reflects value-added engineering, scale and pricing power with pharmaceutical customers. These margin characteristics are structural, supported by proprietary device platforms and long-term supply contracts that preserve profitability through the product lifecycle.
Strategic Capacity Expansion And Product InnovationLarge, committed capacity expansion and new facilities create a durable competitive advantage by enabling scale for big pharma customers, reducing supply constraints and supporting long-term revenue targets. Investment in capacity and platforms underpins future contract wins and market share gains.
Bears Say
Negative Free Cash Flow From High CapExPersistent negative FCF driven by heavy growth CapEx can strain liquidity and force external financing or slower returns to shareholders. Even with solid operating cash conversion, sustained high investment needs create execution and funding risk over the medium term.
Diabetes Care Segment Loss Upon ConsolidationA consolidated loss in Diabetes Care signals profitability challenges in this strategic segment. Diabetes products often require ongoing investment to scale consumables and services; continued losses could demand capital or distract management from higher-margin Delivery Systems growth.
Contract Manufacturing Phaseout Reduces Revenue VisibilityEliminating contract manufacturing removes a revenue source and increases reliance on core device contracts. This transition risks lower utilization, near-term top-line pressure and greater revenue concentration, making forward revenue less diversified and more sensitive to a few large customers.
Ypsomed Holding AG News
YPSN FAQ
What was Ypsomed Holding AG’s price range in the past 12 months?
Ypsomed Holding AG lowest stock price was CHF260.50 and its highest was CHF441.50 in the past 12 months.
What is Ypsomed Holding AG’s market cap?
Ypsomed Holding AG’s market cap is CHF3.82B.
When is Ypsomed Holding AG’s upcoming earnings report date?
Ypsomed Holding AG’s upcoming earnings report date is May 27, 2026 which is in 55 days.
How were Ypsomed Holding AG’s earnings last quarter?
Ypsomed Holding AG released its earnings results on Nov 12, 2025. The company reported CHF10.19 earnings per share for the quarter, beating the consensus estimate of CHF9.11 by CHF1.08.
Is Ypsomed Holding AG overvalued?
According to Wall Street analysts Ypsomed Holding AG’s price is currently Overvalued.
Does Ypsomed Holding AG pay dividends?
Ypsomed Holding AG pays a Annually dividend of CHF2.2 which represents an annual dividend yield of 0.67%. See more information on Ypsomed Holding AG dividends here
What is Ypsomed Holding AG’s EPS estimate?
Ypsomed Holding AG’s EPS estimate is 6.
How many shares outstanding does Ypsomed Holding AG have?
Ypsomed Holding AG has 13,649,739 shares outstanding.
What happened to Ypsomed Holding AG’s price movement after its last earnings report?
Ypsomed Holding AG reported an EPS of CHF10.19 in its last earnings report, beating expectations of CHF9.11. Following the earnings report the stock price went up 4.938%.
Which hedge fund is a major shareholder of Ypsomed Holding AG?
Currently, no hedge funds are holding shares in CH:YPSN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ypsomed Holding AG
Ypsomed Holding AG, together with its subsidiaries, develops, manufactures, and sells injection and infusion systems for pharmaceutical and biotechnology companies. The company operates in two segments, Ypsomed Delivery Systems and Ypsomed Diabetes Care. The Ypsomed Delivery Systems segment provides various injection systems, such as pen injectors, auto injectors, patch injectors, and wearable injectors, as well as other smart devices. This segment offers its products under the YDS brand. The Ypsomed Diabetes Care segment sells and trades in insulin pumps, infusion sets, pen needles, blood glucose monitoring systems, accessories, and other day-to-day items for diabetics. This segment offers its products under the mylife brand name. The company offers precision turned parts; and contract manufacturing and other services. It markets its products through biotechnology and pharmaceutical partners, as well as through its own distribution network and independent distributors. It operates in Switzerland, Europe, North America, and internationally. Ypsomed Holding AG was founded in 1984 and is headquartered in Burgdorf, Switzerland.
Technical Analysis
Options Prices
Currently, No data available
---